Edition:
United Kingdom

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
$1.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
215,902
52-wk High
$3.52
52-wk Low
$0.69

Chart for

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II... (more)
No analyst recommendations are available for .

Overall

Beta: -0.57
Market Cap(Mil.): $17.09
Shares Outstanding(Mil.): 10.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder

* VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

03 Jan 2018

BRIEF-Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13

* REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC : AS OF DEC 13 - SEC FILING Source text: (http://bit.ly/2CNm098) Further company coverage:

20 Dec 2017

BRIEF-Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics

* SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC AS OF DEC 11 - SEC FILING Source text: (http://bit.ly/2ksLZuU) Further company coverage:

14 Dec 2017

BRIEF-Vistagen Therapeutics posts Q2 loss of $0.53 per share

* Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update

09 Nov 2017

BRIEF-Vistagen Therapeutics receives European patent for AV-101 for treatment of depression

* Vistagen Therapeutics receives European patent for AV-101 for treatment of depression Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Vistagen gets FDA authorization to initiate phase 2 study for major depressive disorder

* Vistagen announces fda authorization to initiate phase 2 study of av-101 for major depressive disorder Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-VistaGen Therapeutics files for offering of up to $23 mln of common stock

* VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​ Source text: [http://bit.ly/2zkDNCU] Further company coverage:

18 Oct 2017

BRIEF-Vistagen receives notice of allowance from U.S. Patent And Trademark Office

* Vistagen receives notice of allowance from U.S. Patent and Trademark office for U.S. Patent regarding methods of production for av-101 Source text for Eikon: Further company coverage:

28 Sep 2017

BRIEF-Vistagen to buy up to 1.9 mln shares of common stock at $1.75 per share

* Vistagen announces pricing of underwritten offering of common stock and warrants to purchase common stock

31 Aug 2017

Competitors

Earnings vs. Estimates